Stephen Rubino, Ph.D., MBA
Stephen Rubino, Ph.D., MBA is the Interim CEO of Sporos Bioventures and a member of the Sporos Board of Directors. He is also Executive in Residence and member of the Boards of Directors for Sporos portfolio companies, Asylia Therapeutics and Stellanova Therapeutics. Dr. Rubino has over 30 years of pharmaceutical and biotechnology company experience in the areas of business development & licensing, marketing, commercial operations, and strategic planning across a wide range of therapeutic areas. Dr. Rubino has extensive experience developing and commercializing oncology products both in the US and EU. He is currently a member of the Board of Directors of Viracta, and prior to joining Sporos as Interim CEO, Dr. Rubino served as the Chief Business Officer at Celyad Oncology SA and was a member of the Board of Directors of Sermonix Pharmaceuticals. Previously, he was the Chief Business & Strategy Officer at Omega Therapeutics and Global Head of Business Development and Licensing and New Product Marketing for the Cell and Gene Therapies business unit at Novartis Pharmaceuticals. Dr. Rubino received his Ph.D. in virology from Cornell University and an MBA from Baruch College.